About
About NOXXON Pharma N.V
NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. It is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck & Co. Inc. to study NOX-A12 combined with Keytruda/pembrolizumab inhibitor antibody in patients with metastatic solid tumors. NOXXON Pharma N.V. was founded in 1997 and is based in Berlin, Germany.
5 years, 6 months ago
NOXXON Pharma N.V is currently in a long term downtrend where the price is trading 24.2% below its 200 day moving average.
From a valuation standpoint, the stock is 26.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 200.6.
Based on the above factors, NOXXON Pharma N.V gets an overall score of 1/5.